SMA Capital’s Cogent Biosciences COGT Stock Holding History

SMA Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Buy	287 +130	+83%	+$4.55K	﹤0.01%	101
2026 Q1	$6.04K	Buy	+157	New	+$5.8K	﹤0.01%	80

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SMA Capital's COGT Position: Q2 2026 in Review

SMA Capital increased its Cogent Biosciences (COGT) stake by 83% in Q2 2026, buying an estimated $4.55K and bringing the position to 287 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #101.

SMA Capital first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

SMA Capital held 287 shares of Cogent Biosciences worth $11.1K as of Q2 2026.
SMA Capital bought 130 Cogent Biosciences shares in Q2 2026, an estimated $4.55K.
Cogent Biosciences made up ﹤0.01% of SMA Capital's portfolio in Q2 2026, its #101 holding.
SMA Capital first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.